This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Shattuck_Labs hosts SL-325 data call
Business investor call

Shattuck_Labs hosts SL-325 data call

Analysis based on 9 articles · First reported Jun 05, 2026 · Last updated Jun 05, 2026

Sentiment
20
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The investor call by Shattuck Labs to present Phase 1 clinical data for SL-325 could significantly impact the company's stock price, depending on the data's reception. Positive results could lead to increased investor confidence and a rise in the stock, while negative or underwhelming data could have the opposite effect.

biotechnology pharmaceuticals
Event Summary

Shattuck Labs, a clinical-stage biotechnology company, announced it will host an investor call and webcast on June 8, 2026. The event will feature presentations by members of Shattuck Labs' management team, including Taylor Schreiber (CEO), Lini Pandite (CMO), Suresh De Silva (CSO), Michael Choi (VP of Clinical Development), and Andrew Neil (CFO). They will present comprehensive Phase 1 clinical data for SL-325, a potentially first-in-class DR3 blocking antibody for inflammatory and immune-mediated diseases, covering safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic, and immunogenicity results. A pipeline update will also be provided, followed by a Q&A session. SL-325 is designed to achieve a complete and durable blockade of the DR3/TL1A pathway, with preclinical studies showing high affinity binding and superior activity over TL1A antibodies.

Entities Involved
stock
Shattuck Labs
Shattuck Labs is hosting an investor call to present Phase 1 clinical data for SL-325 and provide a pipeline update, which could positively impact its stock price and investor confidence.
Importance 100.0 Sentiment 20.0
per
Taylor Schreiber
Taylor Schreiber, CEO of Shattuck Labs, will present at the investor call, providing leadership and insight into the company's progress.
Importance 70.0 Sentiment 10.0
per
Andrew Neil
Andrew Neil, CFO of Shattuck Labs, will present at the investor call and is also the investor and media contact, playing a key role in financial communication.
Importance 70.0 Sentiment 10.0
per
Lini Pandite
Lini Pandite, Chief Medical Officer of Shattuck Labs, will present at the investor call, offering expertise on the clinical data.
Importance 60.0 Sentiment 10.0
per
Suresh De Silva
Suresh De Silva, Chief Scientific Officer of Shattuck Labs, will present at the investor call, detailing scientific aspects of SL-325.
Importance 60.0 Sentiment 10.0
per
Michael Choi
Michael Choi, Vice President of Clinical Development at Shattuck Labs, will present at the investor call, focusing on clinical development.
Importance 60.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.